October 15, 2015
Basilea signs exclusive distribution agreement for Zevtera® (ceftobiprole medocaril) in the Middle East and North Africa with Hikma Pharmaceuticals LLC
- Hikma to commercialize antibiotic Zevtera® in the Middle East and North Africa (MENA) region
- Agreement expands the global availability of Zevtera®
Basel, Switzerland, October 15, 2015 - Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today the signing of an exclusive distribution and supply agreement with Hikma Pharmaceuticals LLC for Basilea's broad-spectrum antibiotic Zevtera® (ceftobiprole medocaril)1 for the Middle East and North Africa (MENA) region.
Under the terms of the agreement, Hikma will have the exclusive right to register, distribute and market Zevtera® across the MENA region. Basilea's European regulatory dossier will be the basis for regulatory filings in MENA countries. The financial terms of the agreement were not disclosed.
David Veitch, Basilea's Chief Commercial Officer, stated: "We are very pleased to further expand the commercial availability of Zevtera through the partnership with Hikma, a leading pharmaceutical company in the Middle East and North Africa region. Hikma has a well-established and significant sales force with strong local presence and a successful track record of launching brands in this region. This agreement will potentially enable physicians and patients in the MENA region to benefit from a new option to treat severe bacterial infections."
About Zevtera® (ceftobiprole medocaril)
Zevtera®/Mabelio® (European trade names of ceftobiprole, depending on the country) is a new generation broad-spectrum cephalosporin antibiotic with bactericidal activity against Gram-positive and Gram-negative bacteria associated with pneumonia, including methicillin-resistant Staphylococcus aureus (MRSA) and susceptible Pseudomonas spp.1
Ceftobiprole has received national licenses for the treatment of adult patients with community- and hospital-acquired pneumonia (CAP, HAP), excluding ventilator-associated pneumonia (VAP) in 13 European countries2 and Canada and has been launched in Germany, France, Italy and the United Kingdom.
Basilea Pharmaceutica Ltd. is a biopharmaceutical company developing products that address increasing resistance and non-response to current treatment options in the therapeutic areas of bacterial infections, fungal infections and cancer. The company uses the integrated research, development and commercial operations of its subsidiary Basilea Pharmaceutica International Ltd. to discover, develop and commercialize innovative pharmaceutical products to meet the medical needs of patients with serious and potentially life-threatening conditions. Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland and listed on the SIX Swiss Exchange (SIX: BSLN). Additional information can be found at Basilea's website www.basilea.com.
This communication expressly or implicitly contains certain forward-looking statements concerning Basilea Pharmaceutica Ltd. and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Basilea Pharmaceutica Ltd. to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Basilea Pharmaceutica Ltd. is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.
For further information, please contact:
|Media Relations||Investor Relations|
| Peer Nils Schröder, PhD |
Head Public Relations &
+41 61 606 1102
| Barbara Zink, PhD, MBA |
Head Corporate Development
+41 61 606 1233
This press release can be downloaded from www.basilea.com .
1 Summary of Product Characteristics (SPC): www.mhra.gov.uk
[Accessed: October 14, 2015]
2 European trade name Zevtera® or Mabelio®, depending on the country. The drug has received national licenses in 13 European countries for the treatment of adult patients with community- and hospital-acquired pneumonia (CAP, HAP), excluding ventilator-associated pneumonia (VAP): Austria, Belgium, Denmark, Finland, France, Germany, Italy, Luxembourg, Norway, Spain, Sweden, Switzerland and the United Kingdom.